Some more good news for the advanced prostate cancer community was announced today. Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) has granted priority review to their New Drug Application (NDA) filed in December 2012 for the investigational oncology compound radium-223 dichloride (radium-223). The application is under review for the treatment of men with castration-resistant prostate cancer (CRPC) with bone metastases.

“We are pleased that the FDA has granted priority review status to radium-223 for the treatment of patients with CRPC that has metastasized to the bones as it supports our ongoing effort to make this compound available as early as possible for patients in need of new treatment options,” said Kemal Malik, MD, Member of the Bayer HealthCare Executive Committee and Head of Global Development.

The FDA has a priority review process